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Abstract
Background: An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to
substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on
implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria
in children in Mozambique. Further evidence of its protective efficacy will be gained in a pivotal, multi-centre,
phase III study. This paper describes the case definitions of severe malaria used in this study and the programme
for standardized assessment of severe malaria according to the case definition.
Methods: Case definitions of severe malaria were developed from a literature review and a consensus meeting of
expert consultants and the RTS, S Clinical Trial Partnership Committee, in collaboration with the World Health
Organization and the Malaria Clinical Trials Alliance. The same groups, with input from an Independent Data
Monitoring Committee, developed and implemented a programme for standardized data collection.
The case definitions developed reflect the typical presentations of severe malaria in African hospitals. Markers of
disease severity were chosen on the basis of their association with poor outcome, occurrence in a significant
proportion of cases and on an ability to standardize their measurement across research centres. For the primary
case definition, one or more clinical and/or laboratory markers of disease severity have to be present, four major
co-morbidities (pneumonia, meningitis, bacteraemia or gastroenteritis with severe dehydration) are excluded, and a
Plasmodium falciparum parasite density threshold is introduced, in order to maximize the specificity of the case
definition. Secondary case definitions allow inclusion of co-morbidities and/or allow for the presence of
parasitaemia at any density. The programmatic implementation of standardized case assessment included a clinical
algorithm for evaluating seriously sick children, improvements to care delivery and a robust training and evaluation
programme for clinicians.
Conclusions: The case definition developed for the pivotal phase III RTS, S vaccine study is consistent with WHO
recommendations, is locally applicable and appropriately balances sensitivity and specificity in the diagnosis of
severe malaria. Processes set up to standardize severe malaria data collection will allow robust assessment of the
efficacy of the RTS, S vaccine against severe malaria, strengthen local capacity and benefit patient care for subjects
in the trial.
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Malaria remains a considerable burden despite progress
in implementation of malaria control policies. It is esti-
mated that malaria causes 709,000 deaths every year in
Africa; 85% in children less than five years of age [1].
Used in conjunction with existing interventions such as
indoor residual insecticidal spraying, long-lasting insecti-
cide-impregnated bed nets, intermittent preventive anti-
malarial therapy in pregnancy, and prompt treatment
with an effective anti-malarial, an effective malaria vac-
cine for young children in Africa has the potential to
reduce the burden of the disease substantially.
The malaria vaccine at the most advanced stage of
development is RTS, S, a pre-erythrocytic vaccine candi-
date containing Plasmodium falciparum circumsporo-
zoite surface antigen. This vaccine is formulated with
new proprietary Adjuvant Systems - AS01 or AS02 [2].
Earlier studies have demonstrated the potential of RTS,
S/AS02 [3,4] and RTS, S/AS01 to provide partial protec-
tion against uncomplicated malaria [5]. In addition to
prevention of uncomplicated malaria, one of the main
aims of malaria vaccines is to prevent severe malaria.
Although severe malaria can present in many different
ways, typical symptoms in young children include severe
anaemia, respiratory distress, hypoglycaemia, repeated
seizures, acidosis, prostration and fever [6]. Severe
malaria is most commonly caused by P. falciparum, and
i na r e a so fs t a b l ee n d e m i c i t yi sm a i n l yad i s e a s eo fc h i l -
dren under five years of age [6].
Efficacy against severe malaria is a key factor that will
determine evidence-based decisions on the implementa-
tion of new malaria control tools [7,8]. Evidence from
phase II RTS, S trials showed the vaccine can provide
protection against severe disease. In the proof-of-con-
cept study conducted in Mozambique, the RTS, S/AS02
vaccine prevented 49% (95% CI 12-71) of severe malaria
episodes during 18 months of follow-up [4]. In a study
in Kenya and Tanzania, out of 809 children, half of
whom had received RTS, S/AS01, one case of severe
malaria was reported in the experimental malaria vac-
cine group as compared with eight in the control group,
over an eight months follow-up period [5]. These
encouraging results need confirmation in a larger phase
III multicentre study with a robust and standardized
assessment of cases of severe malaria.
Previous multi-centre studies on severe malaria have
demonstrated that standardized assessment of cases is
challenging [9]. Success depends on the use of common
case definitions, standardized investigation of patients
and the quality of diagnosis and care. Accurate diagnosis
of severe malaria can be difficult because of the diversity
in presentation and because its symptoms overlap with
those of many common febrile childhood illnesses
including pneumonia, meningitis and sepsis [10-12]. For
example, an autopsy study of 31 children diagnosed
with cerebral malaria in Malawi showed that 23% had
died from other causes [13].
The current, internationally accepted definition of
severe malaria in children is based on the need for
prompt treatment of children with a medical history
and clinical presentation compatible with severe malaria,
given the high complication and fatality rate of this con-
dition [6,14]. In clinical practice, the threshold for initia-
tion of anti-malaria treatment needs to be low, and is
sometimes based on syndromic assessment only rather
than on investigation-supported diagnosis. In these cir-
cumstances, a highly sensitive but non-specific case defi-
nition is appropriate to determine treatment. However,
use of a sensitive but non-specific case definition as a
trial endpoint would be expected to result in an under-
estimation of vaccine efficacy [15]. Conversely, by using
ah i g h l ys p e c i f i cb u tp o o r l ys e nsitive case definition, a
large sample size will be required to provide a sufficient
number of cases. An ideal case definition for the pur-
pose of a clinical trial thus needs to combine a level of
specificity that provides an accurate estimate of vaccine
efficacy with a level of sensitivity that optimizes the
power of the study [16,17]. A World Health Organiza-
tion (WHO) expert study group has developed recom-
mendations on appropriate criteria for severe malaria
case definitions for use as a vaccine trial endpoint [8].
The results of phase II studies led to a decision to
employ the RTS, S/AS01 vaccine formulation for the
pivotal phase III trial. The objectives and design of the
phase III RTS, S/AS01 study are described in a compa-
nion paper [18]. This paper provides a detailed descrip-
tion of the case definitions of severe malaria used for
the trial, the work undertaken to ensure standardized
assessment of severe malaria across different study cen-
ters and the efforts made to ensure optimal patient care.
Severe malaria endpoint case definitions for
evaluation in the RTS, S/AS01 Phase III trial
The case definitions of severe malaria were developed
prospectively through a literature review and consensus
meeting of the Clinical Trial Partnership Committee
(CTPC) severe malaria working group and expert con-
sultants, in collaboration with representatives of the
WHO and the Malaria Clinical Trials Alliance (MCTA).
The CTPC includes representatives of all the research
centres collaborating on the RTS, S clinical development
programme, GlaxoSmithKline and the Malaria Vaccine
Initiative.
The main objective of this discussion was the develop-
ment of a primary case definition which balanced sensi-
tivity and specificity, reflecting true paediatric malaria
cases at risk of an adverse outcome, usually needing
hospital admission, taking into account the fact that
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other co-morbidities can be present.
A retrospective study of 1,361 children admitted to a
Kenyan District hospital and 4,583 community controls
showed how the specificity of a case definition for severe
malaria varied depending upon the intensity of transmis-
sion, the parasite density threshold applied, the markers
of severity that were included and upon how co-morbid-
ities were dealt with during analysis. Among children
under two years old who presented with symptoms
compatible with severe malaria, logistic regression mod-
els showed that the malaria-attributable fraction of these
cases was only 85%. This increased to 89% when chil-
dren with identified co-morbidities (similar to those pro-
posed here) were excluded and to 95% when a threshold
of 2500 parasites/μL was also applied [14].
Table 1 illustrates the primary and secondary case
definitions of severe malaria that will be used in the
analysis of clinical data from the phase III RTS, S/AS01
clinical trial. The primary case definition of severe
malaria will include a parasite density threshold of
>5,000 parasites/μL, and one or more markers of disease
severity. Children with major co-morbidities will be
excluded from the primary case definition. As described
in a companion paper [18], the parasite density thresh-
old selected for clinical malaria (5,000 parasites per μl)
is expected to provide a minimum specificity of 80% for
all age groups and transmission settings. The same
threshold will be used in the definition of severe
malaria. Secondary case definitions with increased sensi-
tivity will also be used. One of the secondary case defi-
nitions will not exclude co-morbidities. In another
secondary case definition, the presence of parasites at
any density will be allowed. Because it is not clear what
proportion of severe malaria cases will be in HIV-
infected children and lack of previous experience on
vaccine efficacy in HIV infected children, a third sec-
ondary case definition will exclude patients with a diag-
nosis of HIV infection (Table 1).
Table 2 presents the clinical and laboratory markers
that will be used to classify patients according to the
case definitions. The clinical markers of disease severity
are prostration, Blantyre coma score of two or less, two
or more seizures and respiratory distress, characterized
by lower chest wall in-drawing and abnormally deep
breathing. The laboratory markers are hypoglycaemia,
metabolic acidosis, lactic acidaemia and severe anaemia.
Co-morbidities excluded from the primary case defini-
tion are pneumonia, meningitis, sepsis and gastroenteri-
tis with severe dehydration.
Markers of disease severity (Table 2)
Many studies have investigated the value of various clin-
ical and laboratory markers as prognostic indicators of
mortality and sequelae in malaria. In 1995, Marsh and
colleagues showed that impaired consciousness, respira-
tory distress and severe anaemia were three central mar-
kers of disease severity associated with adverse outcome,
especially when present together [19]. More recently, a
two-year observational study of children in Gabon with
P. falciparum malaria showed that coma, seizures, lactic
acidaemia, respiratory distress and hypoglycaemia were
independent predictors of death [20]. The highest fatal-
ity rate occurred in children with a combination of
coma/seizures, lactic acidaemia and hypoglycaemia. A
recent study of children in Mali showed that hypogly-
caemia, respiratory distress and deep coma are indepen-
dent predictors of death [21].
Neurological impairments: prostration, Blantyre
coma score, repeated seizures
Neurological impairment is a frequent marker of disease
severity, and can result in long-term neurological seque-
lae [22]. In a retrospective study of patient records col-
lected from 1992 to 2004 in a district hospital in Kenya,
neurological involvement was detected in nearly half of
19,560 children with malaria [23]. The most common
manifestations were seizures (37.5%), prostration (20.6%)
and impaired consciousness or coma (13.2%). Numerous
studies have demonstrated that coma/impaired con-
sciousness and seizures are independently associated
with mortality in African children with malaria
[19-21,24-26]. In this phase III study, prostration, Blan-
tyre coma score <2 and repeated seizures have been
selected as markers of neurological impairment for the
severe malaria case definition.
Prostration was included in the case definition of
severe malaria as an important sign that will allow cap-
ture of many of the children that need hospital admis-
sion, surveillance, and prompt treatment to prevent
Table 1 Case definitions of severe malaria
Primary definition Secondary definition 1 Secondary definition 2 Secondary definition 3
P. falciparum asexual parasitaemia
>5,000 parasites/μL
One or more markers of disease
severity
No co-morbidity
P. falciparum asexual parasitaemia
>5,000 parasites/μL
One or more markers of disease
severity
P. falciparum asexual parasitaemia
>0 parasites/μL
One or more markers of disease
severity
No co-morbidity
P. falciparum asexual parasitaemia
>5,000 parasites/μL
One or more markers of disease
severity
No co-morbidity
No HIV infection
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inability to perform a previously-acquired motor func-
tion, such as standing, sitting or, in very young children,
the ability to suck, and is assessed in a child who is
calm and awake. The trial algorithm for evaluating pros-
tration is shown in Figure 1. Prostration is assessed at
least one hour after control of seizures or
hypoglycaemia.
The Blantyre coma score provides a way of measuring
conscious levels that is relatively easy to standardize
across different sites. A low Blantyre coma score is asso-
ciated with a high risk of an adverse outcome in malaria
[6,27]. The score is based on motor, verbal and eye
movement in response to stimuli. A score of 5 is nor-
mal, although under nine months of age a score of 4
can be normal, as the ability to localize a painful
Table 2 Markers of disease severity included in the severe malaria case definition
Marker of
severity
Definition
Prostration ￿ Inability to perform a previously-acquired motor function:
- Inability to stand in a child previously able to do so
- Inability to sit in a child previously able to do so
- Inability to suck in a very young child
Blantyre score ≤2 ￿ Conscious level scored (0-5) using the Blantyre coma scale [27]. Determined by adding the scores for:
- Best motor response (scored 0-2)
- Best verbal response (scored 0-2)
- Eye movement (scored 0-1)
Seizures, 2 or more ￿ Number of seizures occurring in the total time period including 24 h before admission, the emergency room and
hospitalization
Respiratory distress ￿ Lower chest wall in-drawing or abnormally deep breathing
Hypoglycaemia ￿ Blood glucose <2.2 mmol/L
Metabolic acidosis ￿ Base excess ≤-10.0 mmol/L
Lactic acidaemia ￿ Lactate ≥5.0 mmol/L
Severe anaemia ￿ Haemoglobin <5.0 g/dL
Figure 1 Algorithm for evaluation of prostration.
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score of 2 or less is considered indicative of cerebral
malaria [6,27]. The trial algorithm to evaluate Blantyre
coma score is provided in Figure 2.
Respiratory distress: deep breathing, lower chest
wall in-drawing
Respiratory distress is also an important predictor of
mortality in severe malaria [18-21,25,28-30]. Two speci-
fic markers of respiratory distress have been shown to
be associated with an adverse outcome in malaria and
are, therefore, included in the definition of severe
malaria: abnormally deep breathing and lower chest wall
in-drawing. Abnormally deep breathing is defined as
deep or laboured respiration (acidotic or Kussmaul
respiration) with increased inspiratory excursion and
expiratory incursion of the chest. The respiratory rate
may or may not be increased. Deep breathing is indica-
tive of metabolic acidosis and associated with an
increased risk of mortality in children with malaria
[6,18,30]. The second marker of respiratory distress,
lower chest wall in-drawing, is defined as the inward
movement of the bony structure of the lower chest wall
with inspiration. Chest wall in-drawing was
independently associated with death in a study of 2400
malaria cases in Tanzania [27]. Other respiratory dis-
tress markers, such as nasal flaring or visible inward
movement of intercostal tissues (intercostal recession),
have not independently been shown to be associated
with an adverse outcome in malaria [6].
Metabolic complications; hypoglycaemia, acidosis,
hyperlactacidaemia
Metabolic complications are common in severe malaria,
particularly hypoglycaemia and acidosis [31]. Hypogly-
caemia has been identified as a key prognostic indicator
of high risk of death for children with malaria
[6,18-20,23-25,27,32]. The risk of cognitive impairment
following hypoglycaemia in malaria has also been
described [21]. As no single clinical sign is a pathogno-
monic marker of hypoglycaemia, a blood measurement
is required. In the phase III study, hypoglycaemia will be
defined as a blood glucose concentration <2.2 mmol/L.
Acidosis, associated with lactic acidaemia and a low
serum bicarbonate or base excess, has also been shown
to be associated with an increased risk of mortality in
patients with malaria [18,24,31,33-36]. The physio-
pathology of acidosis in malaria is complex. Studies
Figure 2 The integrated Blantyre coma scale assessment.
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turbances due to the parasitic infection, and a subse-
quent inflammatory response, and for a low circulatory
blood volume [37,38]. The optimal cut-off points for
lactic acidaemia and base excess that predict mortality
have usually been around 5 mmol/L and from -8 to -12
mmol/L, respectively [32,39,40]. In the pivotal phase III
study, acidosis will be defined by a negative base excess
≤-10.0 mmol/L or by lactic acidaemia ≥5.0 mmol/L.
Severe anaemia
Severe malaria anaemia is a frequently overlooked con-
tributor to overall malaria mortality, especially in young
children. Studies have reported case fatality rates from
severe malaria anaemia varying between 5.6% and 16%,
with over 50% of deaths occurring within 24 hours of
admission [18,27]. However, the exact mortality burden
due to severe malarial anaemia is obscured by rapid
transfusion in clinical research settings, which have
enhanced case management practices that are unavail-
able to most children developing severe malaria anaemia
[19,27,41]. Although anaemia is often multifactorial, the
contribution of single or repeated malaria episodes is
well recognized, and illustrated by the impact of malaria
control measures on anaemia and by the peak in hospi-
tal admissions for severe anaemia and blood transfusion
seen during the malaria season [6,42-44]. In the trial,
severe anaemia, defined as a haemoglobin concentration
<5.0 g/dL, has been included as one of the criteria of
severe malaria.
Markers of disease severity that were not
selected for inclusion in the endpoint case
definition
Markers of disease severity included in the case defini-
tion were chosen on the basis of their association with
poor outcome, occurrence in a significant fraction of
cases and an ability to standardize their measurement
across sites. The selected markers also minimized data
redundancy. For example, although circulatory collapse
and delayed capillary refill time predicts mortality in
children with severe malaria [39], it was agreed that
patients with this indicator would be captured by the
presence of prostration or acidosis. Markers of severity
considered but not included were those that apply to
only a small fraction of cases, are difficult to measure in
a standardized way or are not part of accepted clinical
practice or research methodology. For example, renal
failure is not included as it is rarely seen in children
with severe malaria [6]. Although retinal haemorrhage
has been shown to correlate well with cerebral malaria
[45,46], and is predictive of poor outcome [47,48], the
method for monitoring retinal changes [49] would have
been difficult to implement and standardize across sites.
Exclusion from the severe malaria primary case
definition upon presence of co-morbidities
While children in areas of intense malaria transmission
may have P. falciparum parasitaemia and remain see-
mingly healthy, children admitted to hospital with P. fal-
ciparum parasitaemia often have an associated illness
with symptoms which overlap with those of severe
malaria [10,11,50,51]. Thus, parasitaemia in a severely ill
child may sometimes be coincidental and not the cause
of presenting symptoms. Four major, common infections
have clinical features which can overlap with those of
severe malaria: pneumonia, meningitis, sepsis and gas-
troenteritis with severe dehydration.
Pneumonia
Several studies have demonstrated the difficulty of dis-
tinguishing between severe malaria and pneumonia,
both of which are frequently associated with fever,
tachypnoea and respiratory distress [10,52,53]. To cap-
ture cases of pneumonia in the phase III RTS, S/AS01
trial, a chest X-ray will be taken within 72 hours of
a d m i s s i o ni nc h i l d r e nw i t ht a c h y p n o e ao rr e s p i r a t o r y
distress. WHO guidelines on the interpretation of chest
radiographs for the diagnosis of pneumonia in children
will be employed [54], as illustrated in Table 3. Radio-
graphically proven pneumonia will be defined as conso-
lidation or pleural effusion (Table 4).
Meningitis
Reliable clinical differentiation between severe malaria
and meningitis can be difficult, impaired consciousness
and seizures being cardinal symptoms of both [11,55].
Lumbar puncture is needed to confirm a diagnosis of
meningitis, and to contribute to better treatment [56].
Establishing optimal criteria that indicate the need for a
lumbar puncture has been the subject of considerable
debate in all settings, and should be influenced by the
background epidemiology of diseases affecting the cen-
tral nervous system and meninges in the study area as
well as by the availability of laboratory support. In
malaria-endemic countries, the threshold for undertak-
ing lumbar puncture should be low in order to differ-
entiate between cerebral malaria and meningitis [11,57].
In the phase III RTS, S/AS01 trial, a lumbar puncture
will be performed in the absence of contra-indications
in children with an altered state of consciousness or sei-
zures (excluding simple febrile seizures and seizures
without fever in a known epileptic child). Patients with
a cerebrospinal fluid (CSF) white blood cell (WBC)
count ≥50 × 10
6/L, a positive culture of an organism
known to cause meningitis, or a positive Hib, pneumo-
coccal or meningococcal latex agglutination antigen
detection test will be excluded from the primary case
definition of severe malaria( T a b l e4 )[ 5 8 ] .Ah i g hC S F
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bral malaria without meningitis can cause mild elevation
of CSF WBC counts; patients with meningitis are likely
to have WBC counts that are considerably higher than
50 × 10
6/L [59]. This definition allows cases of cerebral
malaria with only a mild increase in WBC count to be
included in the primary analysis.
Bacteraemia
Bacteraemia is common, and associated with a high
mortality, in children admitted to hospital in sub-
Saharan Africa [49]. Several studies have shown that
invasive bacterial infections, clinically indistinguishable
from severe malaria, are often under-diagnosed in
malaria-endemic areas [50,60-62]. For this reason, all
children in the phase III RTS, S/AS01 trial admitted to
hospital for medical reasons (excluding planned admis-
sions and surgical conditions) will have a blood culture
taken on admission. Capture of cases of sepsis will be
allowed up to 72 hours after admission (Table 4). Blood
culture will be considered positive if a definite pathogen
is isolated (for example, Streptococcus pneumoniae,
Streptococcus agalactiae, Streptococcus pyogenes, Haemo-
philus influenzae, Salmonella spp.) or a bacteria that
could be either a pathogen or a contaminant is isolated
within 48 hours of incubation (for example, Escherichia
coli, Klebsiella pneumoniae, Staphylococcus aureus,
Enterococcus faecalis) [63].
Table 3 Chest X-ray interpretation (WHO 2001)
Classification of quality of chest x-rays
Quality X-ray parameters Classification of quality of chest x-rays (enter result in CRF)
￿ ID on the right side
￿ Position: clavicles and ribs symmetric on each side of the spine
￿ Boundaries: rib cage and costophrenics angles seen
￿ Inspiration: dome of the diaphragm is below the anterior tip of the
6th right rib
￿ Movement: heart, diaphragm, central vessels and ribs sharply defined,
without blurring
￿ Exposure: vascular shadows can be seen in lung periphery, thoracic
vertebrae and large lower lobe vessels visible through cardiac
silhouette
￿ Contrast: background outside patient’s silhouette is black. Bones and
airway easily distinguished from soft tissue
￿ Uninterpretable: if the features of the image are not interpretable
without additional images. No further reading should be made for such
images
￿ Suboptimal: if the features allow interpretation of primary endpoint but
not of other infiltrates or findings. No entries should be made for other
infiltrates for such images
￿ Adequate: if the features allow confident interpretation of endpoint as
well as other infiltrates
Classification of findings of chest x-rays
￿ Consolidation or pleural effusion :
▪ where consolidation is defined as a dense opacity that may be a fluffy consolidation of a portion or whole of a lobe or of the entire lung,
often containing air bronchograms*
▪ where pleural effusion is defined if it occurs in the lateral pleural space (and not just in the minor or oblique fissure) and is spatially
associated with a pulmonary parenchymal infiltrate (including other infiltrate) or if the effusion obliterates enough of the hemithorax to obscure
an opacity
* atelectasis of an entire lobe that produces a dense opacity and a positive silhouette sign with the mediastinal border will be considered
to be an endpoint consolidation
￿ Other infiltrate linear and patchy densities (interstitial infiltrate) in a lacy pattern involving both lungs, featuring peribronchial thickening and
multiple areas of atelectasis. Lung inflation is normal to increased. It also includes minor patchy infiltrates that are not of sufficient magnitude to
constitute primary end-point consolidation, and small areas of atelectasis which in children can be difficult to distinguish from consolidation.
￿ No consolidation, infiltrate or effusion
Table 4 Criteria for diagnosis of co-morbidities to be excluded from the primary case definition of severe malaria
Criteria for co-morbidity Definition
Radiographically proven
pneumonia
￿ Consolidation or pleural effusion on a chest X-ray taken within 72 h of admission
Meningitis on cerebrospinal fluid
examination
￿ White cells ≥50 × 10
6/L or positive culture of compatible organism or latex agglutination antigen detection
test positive for Hib, pneumococci or meningococci
Sepsis (positive blood culture) ￿ Blood culture taken within 72 h of admission is considered positive if:
- A definite pathogen is isolated (e.g. Streptococcus pneumoniae, S agalactiae, S pyogenes, Haemophilus
influenzae, Salmonella spp.)
- A bacteria that could be either a pathogen or a contaminant is isolated within 48 h of incubation (e.g.
Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Enterococcus faecalis)
Gastroenteritis with dehydration ￿ A history of 3 or more loose or watery stools in previous 24 h and an observed watery stool with decreased
skin turgor (>2 seconds for skin to return following skin pinch)
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For the purposes of the trial, gastroenteritis with severe
dehydration will be defined as a history of three or
more loose or watery stools in the previous 24 hours
and an observed watery stool with decreased skin turgor
(>2 seconds for the skin to return to normal following a
skin pinch) (Table 4). It was considered that this defini-
tion would allow the exclusion of cases of gastro-enteri-
tis with dehydration severe enough to be the cause of
prostration or acidosis but not cases of mild diarrhoea
frequently associated with malaria. Decreased skin tur-
gor is a key marker of severe intra-cellular dehydration,
and so more typical of severe gastroenteritis than severe
malaria. The exclusion of gastroenteritis cases with
reduced skin turgor [64] will increase the specificity of
the severe malaria endpoint [14].
Co-morbidities associated with malaria may not always
be a coincidental, unrelated event. This is clearly
demonstrated for invasive bacterial diseases, especially
those due to Gram negative bacteria that can be a com-
plication of severe malaria [ 6 5 ] .I tw i l lb ei m p o r t a n tt o
know whether the malaria vaccine impacts on diseases
other than malaria, through an indirect effect, as sug-
gested by a previous phase II trial of RTS, S/AS01 [5]
and by results from bed net trials [66]. Vaccine efficacy
against severe malaria defined according to secondary
case definitions, where patients with co-morbidities are
not excluded from the analysis, will also be measured
(Table 1).
Implementation of standardized patient
assessment
An algorithm for the evaluation of seriously sick chil-
dren has been created to facilitate standardized identifi-
cation and documentation of severe malaria and co-
morbidities across research centres (Figure 3). This sys-
tematic assessment of hospital admissions will also pro-
mote the early diagnosis and treatment of these
conditions.
The standardized management algorithm will require
that for all acute hospital admissions (excluding trauma
and planned admission), a blood sample is taken for the
evaluation of haemoglobin, glucose, lactate, base excess,
parasitaemia and blood culture, and that a case report
form is completed. The decision to perform a lumbar
puncture or chest X-ray will be made according to spe-
cific indications for each procedure and, in addition, if
the clinician judges such an investigation likely to be
useful to guide management. As far as possible, proce-
dures and evaluations will be carried out in a child-
friendly, relaxed environment, in the presence of a par-
ent. Lumbar puncture will be indicated when children
present with prostration, meningism (stiff neck or bul-
ging fontanel), reduced conscious level (abnormal
Blantyre coma score), or seizure other than a simple,
generalized febrile seizure defined as one associated
with fever, lasting ≤ 5 minutes, followed by no neurolo-
gical abnormalities other than post-ictal sleep, and
occurring in a child ≥ 6m o n t h sw i t hf u l lr e c o v e r y
within 1 hour. If there are signs of raised intracranial
pressure, if there is no access to the puncture point or if
lumbar puncture would compromise the child’sr e s p i r a -
tory efforts, then lumbar puncture will be delayed until
after the patient’s condition has stabilized. A chest X-ray
will be done if there is tachypnoea or respiratory dis-
tress, especially lower chest wall in-drawing or abnor-
mally deep breathing.
Implementation of standardized patient assessment is
supported by a rigorous training and accreditation pro-
gramme for all clinicians involved in patient care,
including regular monitoring and evaluation during the
trial. An online training and accreditation resource will
be available to facilitate new staff training or refresher
training of accredited staff if necessary.
Other provisions for optimizing general patient care,
which were implemented in preparation of the trial, are
summarized in Table 5. These include regular meetings
of a Patient Care Forum, which gave lead clinicians
from all centres the opportunity to discuss important
areas of patient care, vaccine safety and reporting, clini-
cal data collection and medical management of specific
conditions. Copies of the WHO ‘Pocket Book of Hospi-
tal Care for Children - Guidelines for the Management
of Common Illnesses with Limited Resources’ [67] were
distributed and defined as a reference for hospital care,
Figure 3 Algorithm-based evaluation of severely sick children.
1 simple febrile seizure is defined as associated with fever, lasts for
5 minutes or less, generalized as opposed to focal, not followed by
transient or persistent neurological abnormalities, occurring in a
child ³ 6 months of age, with full recovery within 1 hour;
2 BCS < 5
except in infants ≤ 9 months of age < 4, in association with best
motor response of 1;
3 ≥ 50 breaths/minute in children under 1
year of age, and ≥ 40 breaths/minute in children over 1 year of age.
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Page 8 of 12complementing local recommendations. Two doctors
per research centre were trained in Paediatric Advanced
Life Support. Access to recommended malaria control
tools, such as impregnated bed nets and efficacious anti-
malaria treatment is being facilitated.
The severe malaria case definitions described in this
paper have been adopted for evaluation of vaccine
efficacy against severe malaria at the trial analysis
stage, and their use will not compromise the ability of
study physicians to treat study children who present
unwell with malaria, regardless of whether the criteria
of standardized trial case definition are met, accord-
ing to international guidelines and national recom-
mendations. These are reviewed in one of the
modules in the training and accreditation programme
for investigators, covering aspects such as triage, nur-
sing, emergency care, treatment of hypoglycaemia,
convulsions, acidosis and anaemia (including precau-
tions for blood transfusion), and use of antibiotics
and anti-malarials.
The infrastructure of study centres has been improved
to ensure that patients have standardized access to the
assessment and diagnostic techniques needed for the
study. This required patient access to care to be facili-
tated, wards to be refurbished and the introduction or
strengthening of radiological and microbiological capaci-
ties (Table 4). These improvements to local facilities will
remain beyond the trial and benefit the community at
large. The clinical research know-how and infrastruc-
tures will reinforce the ability of research centres to
diversify the research agenda, thereby reinforcing the
sustainability of these improvements.
Conclusion
Severe malaria has been identified by a WHO expert
study group as an important endpoint for trials of
malaria vaccines [8]. Its public health burden is suffi-
ciently great to warrant its inclusion as a key endpoint
and evidence of efficacy against severe malaria is likely
to encourage implementation decisions when a vaccine
becomes available. However, severe malaria is difficult
to define, mainly because of the diversity in its clinical
presentation and the frequent overlap of symptoms with
other common illnesses. The definitions commonly used
to diagnose severe malaria in clinical practice are not
sufficiently specific for use in vaccine trials.
I nt h ep r e s e n ts t u d y ,t h ep rimary and secondary case
definitions reflect the presentation of severe malaria that
typically leads to hospitalization of young children in
Africa. Furthermore, they are in accordance with the
recommendations of the WHO [8], are locally applicable
and appropriately balance sensitivity and specificity for
the purpose of a clinical trial. A robust implementation
programme ensures standardization of measurements
across research centres. Furthermore, children will bene-
fit from the diagnostic investigations introduced and the
optimized clinical management of severe malaria cases.
These strengthened capacities will benefit the local
communities.
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￿ Distribution of WHO Pocket Book of Hospital Care for Children ￿ Assure access to recommended prevention and
treatment approaches:
￿ Improvements to care delivery that benefit the wider community ▪ Bed nets to be distributed during screening process
in areas with no bed net access
￿ Improved infrastructure, wards refurbishment, introduction of new diagnostic
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▪ Where available, normal distribution channels
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diagnostic techniques or specialized care required
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